Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Informatics and Bioimaging Center Combines Resources, Expertise from UMD, UMB

Published: Thursday, November 22, 2012
Last Updated: Thursday, November 22, 2012
Bookmark and Share
Cross-disciplinary center is latest element of MPowering the State initiative between the two campuses.

A new center that combines advanced computing resources at the University of Maryland, College Park (UMD) with clinical data and biomedical expertise at the University of Maryland, Baltimore (UMB) could soon revolutionize the efficiency and effectiveness of health care in the state of Maryland and beyond.
 
The Center for Health-related Informatics and Bioimaging (CHIB) announced today joins computer scientists, life scientists, engineers, physicists, biostatisticians and others at the College Park campus with imaging specialists, physicians, clinicians and additional health experts in Baltimore.
 
These cross-institutional teams will work on projects that apply major advances in computing power to grand challenges in genomics, health records management and in analyzing massive amounts of data available from new imaging technologies.
 
Ultimately, officials say, the research at CHIB will advance the concept of personalized medicine, where decisions and practices are tailored to individual patients through the use of genetic sequencing and other biomedical information.
 
"This is exactly the type of collaborative science, leveraging the strengths of each institution, we anticipated when launching MPowering the State last spring,"  says UMD President Wallace Loh.
 
MPowering the State is the strategic partnership between UMD and UMB intended to significantly expand research collaborations, business development and student opportunities at both institutions.
 
"Our cross-institutional researchers, together with our clinicians, are helping open the doors to personalized medicine,"  says UMB President Jay A. Perman.  "CHIB is going to help us move more quickly from basic research to therapeutics to patient care. As a physician, I' m excited about what this will mean for health care in Maryland and the region."
 
Leadership of the joint center will be split between the two campuses: Amitabh Varshney, professor of computer science and director of the university' s Institute for Advanced Computer Studies (UMIACS), will lead efforts in College Park; Owen White, associate director for bioinformatics at the Institute of Genome Sciences and professor in the School of Medicine, will direct CHIB activities in Baltimore.
 
"There's been a surge of new data related to genomics and proteins," says Varshney. "We believe our computing resources at UMIACS can help our colleagues in Baltimore identify specific disease markers to address serious health concerns like cancer, diabetes or autism."

The new center will take full advantage of recent discoveries in science and technology. CHIB will benefit from significant advances in computing power over the past decade, including the development of multicore systems and cloud computing, as well as new methods of organizing, visualizing and analyzing massive amounts of data derived from high-throughput laboratory systems.

Using these approaches, CHIB will play a central role in facilitating genomic research, medical information management and translational science development.

"The School of Medicine and Institute of Genome Sciences bring together multidisciplinary teams of researchers who are taking cutting-edge research and translating this knowledge into diagnostics, vaccines and therapeutics," says UMB's White.

Researchers say the wealth of patient data available at Baltimore's medical school allows an unprecedented opportunity to link basic biological data and clinical concepts that can be used to improve diagnostic efforts and patient care.

The CHIB branch at College Park, housed within UMIACS, is supported by almost $1 million in seed funding from the provost 's office, the Division of Research and colleges and schools whose research faculty are involved. A similar funding mechanism at UMB will support efforts in Baltimore.

"The new center strengthens our mission of using a truly multidisciplinary approach in addressing grand challenges in medicine and health care," says Jayanth Banavar, dean of UMD' s College of Computer, Mathematical, and Natural Sciences, which provided part of the startup funding for the CHIB in College Park.

"It is expected that the cross-institutional CHIB teams will secure additional federal funding from the National Institutes of Health or the National Science Foundation as research efforts move forward," says Patrick O’Shea, UMD's vice president for research and chief research officer. "The federal agencies recognize, just as we do, that transformational discoveries demand a dedicated, multifaceted approach," he says.

There are also plans for researchers at CHIB to leverage the region's bioscience/biotech strengths to commercialize any new technologies they discover.

"The state of Maryland is already home to one of the largest bioscience clusters in the country, and a significant portion of the U.S. pharmaceutical industry is within a few hours of these universities," says Bruce Jarrell, senior vice president and chief academic and research officer at UMB.  "By continuing to intertwine the research and clinical resources of our universities, we can provide fuel for the growth of the commercial health-care sector."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
Wednesday, October 14, 2015
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Wednesday, July 22, 2015
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!